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Background and aims: The effects of low dose prednisolone on circulating markers of 2 
endothelial function, the arginine metabolites asymmetric dimethyl arginine (ADMA), mono 3 
methyl arginine (MMA), and homoarginine, are uncertain. We assessed whether patients with 4 
rheumatoid arthritis have perturbations in arginine metabolite concentrations that are reversed 5 
by low dose prednisolone. 6 
Methods: Eighteen rheumatoid arthritis patients who had not taken prednisolone for >6 7 
months (non-glucocorticoid (GC) users), 18 patients taking continuous oral prednisolone 8 
(6.5±1.8 mg/day) for >6 months (GC users) and 20 healt y controls were studied. Fasting 9 
plasma concentrations of ADMA, MMA, and homoarginine were measured by ultra-10 
performance liquid-chromatography. Baseline data from non-GC users were compared with 11 
healthy controls to assess the effect of rheumatoid arthritis. The change in arginine 12 
metabolites in non-GC users after 7 days of prednisolone (6 mg/day) was used to assess the 13 
acute effects of prednisolone. Baseline data from non-GC users were compared with GC 14 
users to assess the chronic effects of prednisolone.  15 
Results: Non-GC users had higher ADMA (0.59±0.03 vs. 0.47±0.01 µM, p=0.004) and 16 
MMA concentrations (0.10±0.01 vs. 0.05±0.00 µM, p <0.001) than controls. The only 17 
change with acute prednisolone was a reduction in homoarginine (1.23±0.06 vs. 1.08±0.06 18 
µM, p=0.04) versus baseline. GC users had lower concentratio s of ADMA (0.51±0.02 vs. 19 
0.59±0.03 µM, p=0.03) than non-GC users. 20 
Conclusions:  Rheumatoid arthritis patients have higher concentrations of ADMA and MMA, 21 
inhibitors of endothelial function. Chronic, but not acute, prednisolone therapy is associated 22 
with a lower ADMA concentration, suggesting a salutry effect of long-term glucocorticoid 23 

















Rheumatoid arthritis is associated with a 30-60% increased risk of cardiovascular events [1-2 
6] and a 50% increased risk of death from cardiovascul r disease [7]. Glucocorticoids are 3 
often prescribed to patients with rheumatoid arthritis, but there are concerns regarding 4 
potential adverse cardiovascular events in these pati nts already at high cardiovascular risk 5 
[8, 9]. While high dose glucocorticoids are associated with increased cardiovascular events, it 6 
is unclear whether lower doses (e.g., prednisolone <10 mg/day), commonly prescribed long-7 
term, alter cardiovascular risk [10]. Some epidemiological studies have reported an increase 8 
in cardiovascular events with low dose prednisolone, while others have reported no effect 9 
[11, 12]. Furthermore, the sample size and duration of randomized-controlled studies of 10 
glucocorticoid therapy in patients with rheumatoid arthritis are insufficient to assess 11 
cardiovascular events [13, 14]. 12 
 13 
Endothelial dysfunction is a key event in the pathogenesis of atherosclerosis and develops 14 
early in the course of rheumatoid arthritis [15, 16]. A patient’s vasodilatory response to 15 
hypoxia is often used to assess endothelial functio. However, the effect of glucocorticoids 16 
on endothelial function assessed by this approach is uncertain. Endothelial function was 17 
reduced after an increase of glucocorticoid dose in hypopituitary patients [17] and in patients 18 
with IgA nephropathy prescribed glucocorticoids [18]. In contrast, glucocorticoids did not 19 
change endothelial function in healthy adults [19] or patients with rheumatoid arthritis [20]. 20 
Moreover, we recently reported that endothelial function is not affected by acute 21 
prednisolone, but is better in patients on long-term prednisolone [21, 22]. These contrasting 22 
findings suggest that the effects of glucocorticoids on endothelial function might differ 23 
depending on the patient group, the methods used to assess vasodilation, and the dose and 24 















 The measurement of circulating arginine metabolites s an alternative method to assess 1 
endothelial function and cardiovascular risk. Asymmetric dimethyl arginine (ADMA) is a 2 
competitive inhibitor of endothelial nitric oxide synthase (e-NOS), the enzyme that converts 3 
L-arginine to citrulline and releases nitric oxide. ADMA is positively associated with 4 
endothelial dysfunction [23] and cardiovascular mortality [24, 25]. Emerging evidence 5 
suggests that other arginine metabolites also influe ce cardiovascular risk. Mono methyl 6 
arginine (MMA), another inhibitor of e-NOS, and symmetric dimethyl arginine (SDMA), 7 
which reduces L-arginine bioavailability, are also associated with atherosclerosis and 8 
cardiovascular events [26-28]. L-arginine is also metabolized by arginase to ornithine and by 9 
arginine : glycine amidino transferase (AGAT) to homoarginine. Perturbations in these 10 
pathways have also been associated with vascular dysfunction and increased cardiovascular 11 
mortality [29, 30].  12 
 13 
Increased ADMA concentrations in patients with rheumatoid arthritis have been linked to 14 
endothelial dysfunction and impaired endothelial repair [31, 32]. However, little is known 15 
about the effect of rheumatoid arthritis on other arginine metabolites. High dose 16 
glucocorticoids increased ADMA in patients with IgA nephropathy [18] and arginase activity 17 
in an animal model [33]. However, it is not clear whether the typical therapeutic 18 
glucocorticoid doses prescribed to patients with rheumatoid arthritis affect arginine 19 
metabolite concentrations.  20 
 21 
We hypothesized that 1) patients with rheumatoid arthritis have alterations in arginine 22 
metabolism that will influence the effect of prednisolone on endothelial function and 2) the 23 
acute and chronic effects of prednisolone on arginine metabolism differ. Consequentially, the 24 















perturbations in arginine metabolism and then to asses  the acute and chronic effects of low 1 
dose prednisolone on arginine metabolism in patients with rheumatoid arthritis.  2 
 3 
Patients and methods 4 
Subjects and study design 5 
Subjects with rheumatoid arthritis aged 50 years or older were recruited from the 6 
rheumatology outpatient clinic at Repatriation General Hospital, Adelaide, Australia and 7 
healthy controls from the general community. We studied 18 subjects who had not been 8 
administered any oral glucocorticoids for at least 6 months (non-GC users), 18 subjects 9 
taking a stable continuous oral prednisolone dose of 4-10 mg/day for at least 6 months (GC 10 
users) and 20 healthy controls with no history of inflammatory disease. The groups were 11 
matched for age, sex and renal function and subjects on oral hypoglycaemic agents and /or 12 
insulin were excluded from the study.  First, we compared arginine metabolite concentrations 13 
in non-GC users and controls to assess the effect of rheumatoid arthritis on arginine 14 
metabolism. Secondly, non-GC users were studied before and after a 7 day course of oral 15 
prednisolone 6 mg daily to determine the acute effects of prednisolone. Finally, baseline data 16 
from non-GC users were compared with data from GC users to determine the chronic effects 17 
of prednisolone. 18 
 19 
The study was approved by the Southern Adelaide Clinical Human Research Ethics 20 
Committee, Flinders Medical Centre, and all subjects provided written informed consent in 21 
accordance with the 1975 Declaration of Helsinki. The primary analyses of this study 22 
investigated the effect of prednisolone on clinical measures of vascular function and energy 23 
and substrate metabolism in the rheumatoid arthritis patients; these have previously been 24 
















Study protocol 2 
Subjects attended the Endocrine Research Unit at Repatriation General Hospital at 0830 h 3 
after a 12 h overnight fast. All subjects took their r gular medications in the morning prior to 4 
arrival, including prednisolone. Basic anthropometric measures were recorded. In each study 5 
participant, fasting blood samples were collected in EDTA tubes for measurement of 7 key 6 
components of arginine metabolism that are directly or indirectly involved in the regulation 7 
of endothelial function: arginine, homoarginine, citrulline, ornithine, ADMA, MMA and 8 
SDMA. Blood samples were centrifuged at 4,000 rpm at 40 Centigrade for 10 min and plasma 9 
frozen at -800 Centigrade until analysis. 10 
 11 
Arginine metabolomics 12 
Samples were prepared for analysis by solvent preciitation. 100 µL of sample was mixed 13 
with 400 µL of assay precipitating solution (0.1% formic acid in methanol), centrifuged for 5 14 
min at 16,000 g, and a 400 µL aliquot of the resulting supernatant evaporated to dryness. 15 
Dried eluates were then reconstituted in 200 µL ammonium formate for liquid 16 
chromatography-mass spectrometry (LC-MS). Chromatogr phic separations were performed 17 
on a Waters ACQUITYTM T3 HSS C18 analytical column (150 mm × 2.1 mm,1.8 µm; 18 
Waters Corp., Milford, USA) using a Waters ACQUITY Ultra Performance LCTM system. 19 
Column elutant was monitored by mass spectrometry, performed on a Waters Quad-Time of 20 
Flight PremierTM quadrupole [35]. 21 
 22 
Other laboratory analysis 23 
Serum creatinine was measured using Roche automated clinical chemistry analyser (Roche 24 















glomerular filtration rate (eGFR) was measured using the Chronic Kidney Disease- 1 
Epidemiology collaboration equation (CKD-EPI equation). C-reactive protein (CRP) was 2 
measured using a Tinaquant immunoturbidimetric assay (Roche Diagnostics GMBH, 3 
Mannheim, Germany) on a Roche Modular Analyser (Hitachi High-Technologies 4 
Corporation, Tokyo, Japan). The between-run coeffici nt of variation  was 3.6 % at a CRP of 5 
3.9 mg/L and 2.3 % at a CRP of 49.5 mg/L. 6 
 7 
Statistical analysis 8 
Statistical analysis was performed using IBM SPSS version 20 for Windows (IBM, New 9 
York, USA). A p-value of <0.05 was considered statistically significant. Subject 10 
characteristics are presented as mean ± standard deviation if the distribution was Normal and 11 
median (interquartile range) if the distribution was not Normal. All other data are presented 12 
as mean ± standard error of mean. Subject characteristics in the three groups were compared 13 
using one-way analysis of variance. Non-GC users were compared to controls using unpaired 14 
t-tests if normally distributed or Mann-Whitney U tests if the distribution was not normal. 15 
Changes in variables in non-GC users after 7 days prednisolone were analysed using paired t-16 
tests. Hereafter in the manuscript these results are reported as the acute effects of 17 
prednisolone. GC users were compared with baseline data from non-GC users using unpaired 18 
t-tests if normally distributed or Mann-Whitney U tes s if the distribution was not normal. 19 
Differences between these two groups are reported in the manuscript as the chronic effects of 20 
prednisolone. In cross-sectional analyses, if a variable was significant in univariate analysis it 21 
was corrected for potential confounders using analysis of covariance. 22 
 23 
The primary end point of this analysis was the difference in concentration of ADMA. A 24 















difference in ADMA assuming a standard deviation of 0.07. In the longitudinal study, a 1 
sample size of 18 per group had 80 % power to detect a 0.05 µM difference in ADMA 2 
assuming a standard deviation of 0.07. 3 
 4 
Results 5 
Subject characteristics 6 
There were no significant differences in sex, age, body mass index, eGFR, smoking, history 7 
of hypertension, ischemic heart disease or diabetes between the three groups (Table 1). GC 8 
users were taking a mean prednisolone dose of 6.5 ± 1.8 mg/day, with a median duration of 9 
continuous prednisolone therapy of 48 (6-240) months. T ere was no significant difference in 10 
C-reactive protein (1.6 (0.5-7.6) vs. 2.4 (1.1-4.5) mg/L, p=0.44), or in the number of patients 11 
taking disease modifying anti-rheumatic drug use (11 vs. 9, p= 0.50) between GC and non-12 
GC users. 13 
 14 
Arginine metabolomics  15 
Effect of rheumatoid arthritis 16 
In univariate analyses, ADMA (0.59 ± 0.03 vs. 0.48 ± 0.01 µM, p=0.004), MMA (0.10 ± 17 
0.01 vs. 0.05 ± 0.00, p <0.001), arginine (93.9 ± 4.8 vs. 75.0 ± 2.3 µM, p=0.001) and 18 
citrulline (37.1 ± 2.2 vs. 29.3 ± 1.1 µM, p=0.002) concentrations were higher in non-GC 19 
users than in controls. The higher concentrations of ADMA ( p=0.008, Fig. 1A), MMA (p 20 
<0.001, Fig. 1B), arginine (94.3 ± 4.2 vs. 75.0 ± 4.2 µM, p=0.003) and citrulline (37.1 ± 1.4 21 
vs. 28.7 ± 1.4 µM, p <0.001) in non-GC users remained significant after adjustment for age, 22 
sex, eGFR, smoking and cholesterol. There were no significant differences in SDMA (0.69 ± 23 
0.06 vs. 0.56 ± 0.04, p=0.08), ornithine (52.3 ± 3.7 vs. 56.8 ± 3.3, p=0.37) and homoarginine 24 















Acute effects of prednisolone 1 
Homoarginine concentration was significantly lower (∆ -0.15 ± 0.07 µM, p=0.04) after 7 2 
days prednisolone. There were no significant changes in ADMA (∆ -0.02 ±  0.02 µM, 3 
p=0.47), MMA (∆ -0.002 ± 0.003 µM, p=0.70), SDMA (∆ -0.08 ± 0.05 µM, p=0.14), 4 
arginine (∆ -5.2 ± 5.0 µM, p=0.31), citrulline (∆ +0.2 ± 1.6 µM, p=0.90) or ornithine (∆ +7.8 5 
± 4.0 µM, p=0.07) concentrations after acute prednisolone. 6 
 7 
Chronic effect of prednisolone 8 
In univariate analyses, GC users had lower concentrations of ADMA (0.51 ± 0.02 vs. 0.59 ± 9 
0.03 µM, p=0.03) and SDMA (0.53 ± 0.03 vs. 0.69 ± 0.06, p=0.03) than non-GC users. The 10 
lower concentrations of ADMA (p=0.03, Fig. 2A), and SDMA (p=0.02, Fig. 2B) in GC users 11 
remained significant after adjustment for age, sex, eGFR, smoking cholesterol, CRP and 12 
disease modifying anti-rheumatic drug use. There were no significant differences in the 13 
concentrations of MMA (0.09 ± 0.00 vs. 0.10 ± 0.01 µM, p=0.12), arginine (86.3 ± 4.7 vs. 14 
93.9 ± 4.8 µM, p=0.27), citrulline (33.6 ± 2.6 vs. 37.1 ± 2.2 µM, p=0.26), ornithine (59.9 ± 15 
5.5 vs. 52.3 ± 3.7 µM, p=0.26) or homoarginine (1.16 ± 0.06 vs. 1.23 ± 0.06 µM, p=0.42) 16 
between GC and non-GC users.  17 
 18 
Discussion 19 
This study assessed the effects of rheumatoid arthritis on arginine metabolism and then the 20 
acute and chronic effects of low dose prednisolone  arginine metabolism in patients with 21 
rheumatoid arthritis. We demonstrated that patients wi h rheumatoid arthritis had higher 22 
concentrations of ADMA and MMA, endogenous inhibitors f eNOS, than healthy controls. 23 
Acute prednisolone treatment resulted in a small reduction in homoarginine, but there were 24 















on chronic prednisolone treatment had significantly lower concentrations of ADMA and 1 
SDMA than patients not on prednisolone. These findings suggest that rheumatoid arthritis per2 
se is associated with an increase in plasma concentrations of endogenous inhibitors of nitric 3 
oxide synthase, which are likely to contribute to endothelial dysfunction. The reduction in 4 
ADMA and SDMA with chronic, but not acute, prednisolone could provide a mechanism that 5 
explains why clinical measures of endothelial function improves with chronic, but not acute, 6 
prednisolone in this patient group [21, 22].  7 
 8 
In this study, patients with rheumatoid arthritis had higher concentrations of ADMA and 9 
MMA than controls. The finding of increased ADMA in patients with rheumatoid arthritis is 10 
consistent with other studies [31, 32], in whom ADMA is associated with increased carotid 11 
intima media thickness and depleted endothelial progenitor cells [31, 36, 37]. This study 12 
extends these observations by demonstrating that MMA, another inhibitor of eNOS, is also 13 
increased in rheumatoid arthritis. ADMA and MMA are both degraded by dimethyl arginine 14 
dimethyl amino hydrolase (DDAH). DDAH activity is reduced in inflammatory states [38, 15 
39]. Elevations of ADMA and MMA are a potential mechanism underlying endothelial 16 
dysfunction in patients with rheumatoid arthritis. SDMA was also increased by 19%, 17 
although this difference was not statistically significant. This finding may represent a type 2 18 
error, given the relatively small sample size. Alternatively, SDMA is metabolized by 19 
different pathways to ADMA and MMA, and this could explain the discordant results [40].  20 
 21 
Patients with rheumatoid arthritis also had higher plasma concentrations of arginine and 22 
citrulline. However, most of the plasma arginine arises from diet with only a small fraction 23 
synthesized from other amino acids [41], while citrulline is predominantly synthesized from 24 















concentrations are likely to reflect increased protein catabolism in rheumatoid arthritis [43] 1 
and not increased eNOS activity. The concentrations of homoarginine and ornithine were 2 
similar in patients with rheumatoid arthritis and controls. These metabolic pathways have not 3 
been extensively studied in patients with rheumatoid arthritis, although one study also 4 
reported homoarginine is not different in patients with rheumatoid arthritis [44].  Our study 5 
suggests that changes in arginase and AGAT activity do not contribute to endothelial 6 
dysfunction in patients with rheumatoid arthritis. 7 
 8 
The only significant change in arginine metabolites after acute low dose prednisolone 9 
consisted of a reduction in homoarginine concentration. Homoarginine is a weak substrate for 10 
nitric oxide synthase that has been negatively associated with cardiovascular morbidity and 11 
mortality in epidemiologic studies [29, 45]. However, the mechanism underlying this 12 
association is not well understood and the role of this metabolic pathway in rheumatoid 13 
arthritis is unclear [44]. There were no significant changes in inhibitors of eNOS or ornithine, 14 
a marker for arginase activity after acute prednisolone. This is consistent with studies 15 
reporting that acute low dose prednisolone does not affect endothelial function in patients 16 
with rheumatoid arthritis [20, 21].  17 
 18 
In contrast to acute prednisolone and despite greater insulin resistance [21], patients with 19 
rheumatoid arthritis on chronic prednisolone treatment had lower ADMA and SDMA 20 
concentrations than patients with rheumatoid arthritis who were not taking prednisolone. 21 
Previous studies reporting the effects of glucocorti ids on ADMA have been discordant with 22 
lower serum ADMA concentrations in patients with Duchenne’s muscular dystrophy treated 23 
with glucocorticoids [46], but an increase in ADMA, coupled with a reduction in flow-24 















glucocorticoids [18]. Moreover, TNF-alpha inhibitors were also shown to reduce ADMA- 1 
arginine ratio and improve vascular function in patients with rheumatoid arthritis in some 2 
[47], but not all [48], studies. We postulate that the effects of glucocorticoids on arginine 3 
metabolism are influenced by the glucocorticoid dose and underlying disease state. In 4 
patients with an active inflammatory disease, anti-inflammatory treatment is associated with a 5 
reduction in ADMA, possibly via increasing DDAH activi y [38, 39]. The reduction in 6 
ADMA is consistent with better endothelial function i  patients with rheumatoid arthritis 7 
prescribed chronic prednisolone. 8 
 9 
This study does not provide direct insights on the cardiovascular effects of prednisolone. 10 
However, available epidemiologic data suggesting ADMA has an important physiologic role 11 
is strong; an increase in serum ADMA concentration of 0.1 µmol/L was associated with a 27 12 
fold increase in relative risk of an acute coronary event [48]. A reduction in ADMA and 13 
SDMA, together with a higher fasting and postprandil reactive hyperaemia index [21, 22], 14 
suggests that chronic low dose prednisolone treatment in patients with rheumatoid arthritis 15 
may not worsen endothelial function. Given the lack of direct evidence of the cardiovascular 16 
effects of low dose prednisolone in literature, ourstudy give some reassurance that long-term 17 
low dose prednisolone can be used to attenuate disease progression in this patient group 18 
without increasing cardiovascular risk. 19 
 20 
We acknowledge the following limitations of this study. We have only assessed extracellular 21 
concentrations of arginine metabolites and must extrapolate these results to assess 22 
intracellular eNOS activity and vascular function. However, studies of enzyme kinetics have 23 
shown enhanced cellular uptake of methylarginines and increased NOS inhibition with 24 















prednisolne treatment in GC users and this could have affected results. However, the small 1 
sample size precludes subgrouping GC users further based on duration of prednisolone use. 2 
Thirdly, other markers of endothelial dysfunction such as monocyte chemoattractant protein 1 3 
(MCP1), vascular cell adhesion molecule 1 (VCAM 1), Selectins or interleukin 6 (IL6) were 4 
not measured. Fourthly, inherent in any cross-sectional study is the possibility that an 5 
unmeasured variable affected results. However, the groups were well matched for a number 6 
of key variables (Table 1). Finally, our findings cannot be translated to prednisolone doses of 7 
>10 mg/day.  8 
 9 
In summary, patients with rheumatoid arthritis have higher concentrations of ADMA and 10 
MMA, inhibitors of eNOS that could contribute to the endothelial dysfunction associated 11 
with this disease. Acute and chronic prednisolone treatment have differing effects on arginine 12 
metabolomics. While acute prednisolone has little effect, chronic prednisolone reduces 13 
ADMA and SDMA concentrations. Reducing these elevatd inhibitors of nitric oxide 14 
synthesis could explain why endothelial function is better in patients with rheumatoid arthritis 15 
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Table 1: Subject characteristics. 1 
 2 
 3 
Data are mean ± standard deviation.  4 
GC, glucocorticoid; n, number of subjects with a specified variable; BMI, body mass index; 5 








Female (n (%)) 16 (80) 12 (67) 12 (67) 0.57 
Age (years) 63 ± 6 64 ± 7 66 ± 7 0.24 
BMI (kg/m2) 28.6 ± 4.2 28.1 ± 5.2 27.9 ± 6.1 0.95 
e-GFR (ml/min) 82 ± 17 87 ± 19 82 ± 13 0.61 
Smoking (n, %)) 0 (0) 2 (11) 1 (6) 0.32 
Hypertension (n, (%)) 3 (15) 5 (25) 4 (20) 0.63 
Ischemic heart disease (n, (%)) 0 (0) 1 (6) 1 (6) 0.56 
Diabetes (n, (%)) 0 (0) 1 (6) 1 (6) 0.56 
Anti hypertensives (n) 2 5 3 0.58 















Fig.ure legends 1 
Fig. 1: Arginine metabolism. 2 
 Simplified diagram showing the principal pathways of arginine metabolism and nitric oxide 3 
production: ADMA, asymmetric dimethyl arginine; MMA, mono methyl arginine; SDMA, 4 
symmetric dimethyl arginine; AGAT, arginine:glycine amidino transferase; ASS/ASL, 5 
arginosuccinate synthase/arginosuccinate lyase. 6 
 7 



























Fig. 2: Effect of rheumatoid arthritis on ADMA and MMA. 1 
 Plasma concentrations of (A) asymmetric dimethyl arginine (ADMA) and (B) monomethyl 2 
arginine (MMA) in 20 healthy controls (white bar) and in 18 patients with rheumatoid 3 
arthritis who were not taking prednisolone (grey bar). Results are mean ± standard error and 4 
are corrected for age, sex, eGFR, smoking and cholesterol. 5 
A 6 
































































Fig. 3: Effect of long-term prednisolone on ADMA and SDMA. 3 
 Plasma concentrations of (A) asymmetric dimethyl arginine (ADMA) and (B) symmetric 4 
dimethyl arginine (SDMA) in 18 patients with rheumatoid arthritis who were not taking 5 
prednisolone (non-GC users, grey bar), and 18 patients with rheumatoid arthritis on chronic 6 
(>6 months) prednisolone (GC users, black bar). Results are mean ± standard error and are 7 
corrected for age, sex, eGFR, smoking cholesterol, CRP and disease modifying anti-8 






















































1. ADMA, a marker of endothelial dysfunction, is increased in rheumatoid arthritis. 
2. Acute prednisolone in rheumatoid arthritis reduces plasma homoarginine. 
3. Long-term prednisolone is associated with lower ADMA. 
